{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:27:41Z","timestamp":1776364061911,"version":"3.51.2"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.18632\/oncotarget.28602","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:34:41Z","timestamp":1719923681000},"page":"424-438","source":"Crossref","is-referenced-by-count":3,"title":["Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1\/2 and STAT3 signaling regardless of KRAS or BRAF mutational status"],"prefix":"10.18632","volume":"15","author":[{"given":"Jun","family":"Zhang","sequence":"first","affiliation":[{"name":"Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"},{"name":"Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA"},{"name":"Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"},{"name":"Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA"},{"name":"Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"},{"name":"Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA"},{"name":"Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[{"name":"Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"},{"name":"Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA"},{"name":"The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA"},{"name":"Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"37","author":"Peeters","year":"2015","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"2","author":"Taieb","year":"2018","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"e193531","DOI":"10.1001\/jamaoncol.2019.3531","article-title":"Efficacy and Safety of Trifluridine\/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial","volume":"6","author":"George","year":"2020","journal-title":"JAMA Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Hosokawa","year":"2018","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-15-2783","article-title":"TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies","volume":"2","author":"Voest","year":"2016","journal-title":"Clin Cancer Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine\/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study","volume":"3","author":"Bi","year":"2018","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"1","author":"Sato","year":"2017","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/1878-0261.12074","article-title":"Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine","volume":"1","author":"Nakamura","year":"2017","journal-title":"Mol Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3892\/or.2016.5208","article-title":"Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts","volume":"3","author":"Takechi","year":"2016","journal-title":"Oncol Rep"},{"key":"10","first-page":"2032","article-title":"Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells","volume":"7","author":"Takechi","year":"2017","journal-title":"Am J Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Cheng","year":"2015","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"38","author":"Ross","year":"2017","journal-title":"Lancet"},{"key":"13","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S1470-2045(16)30284-4","article-title":"Progression-free survival with regorafenib in gastric cancer","volume":"1","author":"Burki","year":"2016","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jhep.2018.05.034","article-title":"Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib","volume":"6","author":"Ma","year":"2018","journal-title":"J Hepatol"},{"key":"15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2016.11.011","article-title":"Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer","volume":"38","author":"Wang","year":"2017","journal-title":"Cancer Lett"},{"key":"16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-15-0847","article-title":"Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy","volume":"1","author":"Weiss","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/2326-6066.CIR-17-0009","article-title":"A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies","volume":"5","author":"Davila","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1080\/15384047.2015.1113355","article-title":"Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy","volume":"1","author":"El-Deiry","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"1","author":"Reya","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2018.08.002","article-title":"Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies","volume":"5","author":"Bruns","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejca.2017.08.033","article-title":"Potential role of polymorphisms in the transporter genes ENT1 and MATE1\/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer","volume":"8","author":"Miyamoto","year":"2017","journal-title":"Eur J Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-017-0532-x","article-title":"An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia","volume":"1","author":"Chen","year":"2017","journal-title":"J Hematol Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/cas.12907","article-title":"Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma","volume":"10","author":"Chayama","year":"2016","journal-title":"Cancer Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/bjc.2016.128","article-title":"Clinical impact and network of determinants of tumour necrosis in colorectal cancer","volume":"11","author":"M\u00e4kinen","year":"2016","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"3537471","DOI":"10.1155\/2018\/3537471","article-title":"Regulation of Tumor Progression by Programmed Necrosis","volume":"201","author":"Kang","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"26","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41388-018-0555-y","article-title":"Tissue necrosis and its role in cancer progression","volume":"3","author":"Benny","year":"2019","journal-title":"Oncogene"},{"key":"27","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1634\/theoncologist.2019-0240","article-title":"Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib","volume":"2","author":"Duh","year":"2020","journal-title":"Oncologist"},{"key":"28","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/0008-5472.CAN-15-0798","article-title":"Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations","volume":"7","author":"Tang","year":"2015","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1002\/jcp.27239","article-title":"Chemoresistance of cancer floating cells is independent of their ability to form 3D structures: Implications for anticancer drug screening","volume":"23","author":"Iyer","year":"2019","journal-title":"J Cell Physiol"},{"key":"30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12015-016-9664-6","article-title":"Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon Cancer","volume":"1","author":"Nateri","year":"2016","journal-title":"Stem Cell Rev Rep"},{"key":"31","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"6","author":"Carter","year":"2006","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-019-1156-5","article-title":"ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa\/VEGFR2\/ERK pathway","volume":"3","author":"Lin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.7150\/ijbs.65653","article-title":"RhoJ facilitates angiogenesis in glioblastoma via JNK\/VEGFR2 mediated activation of PAK and ERK signaling pathways","volume":"1","author":"Jiang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"34","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-14-0236","article-title":"Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks","volume":"1","author":"Kitao","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"10","author":"Sartore-Bianchi","year":"2019","journal-title":"Eur J Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.phrs.2018.10.011","article-title":"Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?","volume":"13","author":"Gomes","year":"2018","journal-title":"Pharmacol Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"14861","DOI":"10.1038\/s41598-019-50968-6","article-title":"CD44\/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure","volume":"9","author":"Ishii","year":"2019","journal-title":"Sci Rep"},{"key":"38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13046-018-0836-x","article-title":"Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling","volume":"3","author":"Tu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-018-0975-0","article-title":"Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid\/HIF-1\u03b1\/VEGF signalling in MCF-7 breast cancer cells","volume":"3","author":"Ziche","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","article-title":"Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer","volume":"1","author":"de Stanchina","year":"2022","journal-title":"Cancer Discov"},{"key":"41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/0008-5472.CAN-19-2830","article-title":"NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Cancer Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/annonc\/mdx035","article-title":"Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer","volume":"2","author":"Miyamoto","year":"2017","journal-title":"Ann Oncol"},{"key":"43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-020-2558-1","article-title":"Differential effectiveness of tyrosine kinase inhibitors in 2D\/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells","volume":"1","author":"Muntan\u00e9","year":"2020","journal-title":"Cell Death Dis"},{"key":"44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semcancer.2017.11.005","article-title":"Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy","volume":"5","author":"Pirro","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"45","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1158\/1078-0432.CCR-14-0725","article-title":"STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma","volume":"2","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41419-021-04320-4","article-title":"The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib","volume":"1","author":"Wei","year":"2021","journal-title":"Cell Death Dis"},{"key":"47","doi-asserted-by":"publisher","first-page":"102144","DOI":"10.1016\/j.redox.2021.102144","article-title":"Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells","volume":"4","author":"Lim","year":"2021","journal-title":"Redox Biol"},{"key":"48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10456-009-9146-4","article-title":"The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art","volume":"1","author":"Benton","year":"2009","journal-title":"Angiogenesis"},{"key":"49","first-page":"844","article-title":"Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason\u2019s score, microvessel density, and epithelial cell proliferation","volume":"7","author":"Weidner","year":"1995","journal-title":"Lab Invest"},{"key":"50","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/15384101.2017.1320005","article-title":"The CDK4\/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia","volume":"1","author":"El-Deiry","year":"2017","journal-title":"Cell Cycle"},{"key":"51","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"7","author":"Chou","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:27:56Z","timestamp":1719934076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["28602"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28602","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}